Our findings not only fill the research gap regarding the role of DC-STAMP in AML pathogenesis and PANoptosis regulation but also identify a potential therapeutic target for DC-STAMP-high AML patients, offering new strategies to overcome chemoresistance and improve prognosis. Here, DCSTAMP is linked to acute myeloid leukemia.